Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bladder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    703 result(s) found for: Bladder. Displaying page 1 of 36.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004465-33 Sponsor Protocol Number: Cox052006 Start Date*: 2006-12-04
    Sponsor Name:Eero Kaasinen
    Full Title: Oral Celecoxib combined with BCG instillation therapy in treatment of carcinoma in situ (CIS), TaG3 and T1 disease of urinary bladder
    Medical condition: invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10005014 Bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-005431-15 Sponsor Protocol Number: ML 5220 Start Date*: 2008-12-24
    Sponsor Name:ACHG-K.U.Leuven
    Full Title: PHASE III RANDOMIZED CHEMOPREVENTION STUDY OF SELENIUM ON THE RECURRENCE OF NON-INVASIVE BLADDER CANCER
    Medical condition: Bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005014 Bladder carcinoma LLT
    9.1 10005003 Bladder cancer LLT
    9.1 10005004 Bladder cancer NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002760-16 Sponsor Protocol Number: 04/QO603/42 HEXVIX Start Date*: 2005-01-12
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust
    Full Title: A randomised Study of “bluelight” hexyl amino levulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional “white light” transurethral resection of newly diagnosed bl...
    Medical condition: Superficial Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005040-20 Sponsor Protocol Number: 2012-520 Start Date*: 2013-01-09
    Sponsor Name:Rigshospitalet
    Full Title: Effect of Macrodex versus lactated Ringer on coagulation in major surgery. A randomised clincal trial.
    Medical condition: Neoplasma malignum vesicae urinaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10029100 Neoplasm urinary bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002259-15 Sponsor Protocol Number: PCB305/04 Start Date*: 2005-01-24
    Sponsor Name:Photocure ASA
    Full Title: A RANDOMIZED, COMPARATIVE,CONTROLLED PHASE III, MULTICENTER STUDY OF HEXVIX FLUORESCENCE CYSTOSCOPY ANDWHITE LIGHT CYSTOSCOPY IN THE DETECTION OF PAPILLARY BLADDER CANCER AND THE EARLYRECURRENCE RA...
    Medical condition: Malignant neoplasm of bladder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10046518 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005263-27 Sponsor Protocol Number: IPOI-VS-IPOP Start Date*: 2014-01-22
    Sponsor Name:CHU POITIERS
    Full Title: EVALUATION OF EARLY PRE-OPERATIVE INTRAVESICAL INSTILLATION OF MYTOMYCIN-C AFTER TRANSURETHRAL RESECTION OF BLADDER TUMOR COMPARED TO EARLY POST-OPERATIVE INSTILLATION. A RANDOMIZED MULTICENTER ST...
    Medical condition: NON-MUSCLE INVASIVE BLADDER CANCER
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000687-89 Sponsor Protocol Number: ICR-CTSU/2008/10018 Start Date*: 2006-11-20
    Sponsor Name:Institute of Cancer Research
    Full Title: A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder
    Medical condition: Non-muscle Invasive Transitional cell Carcinoma of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003898-98 Sponsor Protocol Number: PDD_vs_WL-TURB_in_pazienti_con_NMIB Start Date*: 2013-11-28
    Sponsor Name:Ospedale San Raffaele
    Full Title: COMPARISON OF WHITE LIGHT TUR VS PHOTODYNAMIC DIAGNOSIS (PDD)- GUIDED TUR AS ASSESSED BY SECOND LOOK TUR FOR THE TREATMENT OF HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Medical condition: high grade non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001026-33 Sponsor Protocol Number: AK2016-1 Start Date*: 2016-06-08
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET
    Full Title: Phase II trial: uPAR PET/CT and FDG PET/MRI for preoperative staging of bladder cancer
    Medical condition: Urinary bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000150-22 Sponsor Protocol Number: T14/2018 Start Date*: 2018-06-05
    Sponsor Name:Turku University Hospital
    Full Title: Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive Mitomycin-C (EMDA-MCC) in patients with high risk non-muscle-invasive bladder carcinoma
    Medical condition: Non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002821-30 Sponsor Protocol Number: 12 Start Date*: 2004-12-09
    Sponsor Name:Institute of Oncology, Vilnius University
    Full Title: Study of the efficacy of intravesical instillations of interleukin-2 in treatment of superficial bladder cancer
    Medical condition: Ta,T1 /G1,G2,G3 superficial bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001942-42 Sponsor Protocol Number: GEMCITABINA INTRAVESCICALE Start Date*: 2007-04-26
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: Pharmacokinetical-clinical study of intravescical gemcitabine in patients with marker lesion of superficial transitional cell carcinoma of the bladder
    Medical condition: Patients with superficial transitional cell carcinoma of the bladder
    Disease: Version SOC Term Classification Code Term Level
    6.1 10005003 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003622-18 Sponsor Protocol Number: TS-004 Start Date*: 2007-10-01
    Sponsor Name:State University Hospital
    Full Title: Efficacy and safety of TachoSil in patients undergoing cystectomy. A pilot study.
    Medical condition: The trial will evaluate the efficacy and safety of TachoSil in patients undergoing cystectomy for bladder cancer and non-malignant bladder disease. TachoSil will be applied to the anastomoses betwe...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000607-41 Sponsor Protocol Number: MMC-BCG-1 Start Date*: 2011-03-04
    Sponsor Name:Centre Hospitalier de Jolimont-Lobbes-Tubize-Nivelles
    Full Title: A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer.
    Medical condition: Patients with intermediate/high risk non-muscle invasive bladder cancer (NMIBC) • intermediate risk tumours – Ta, T1 Grade 1, Grade 2, multifocal and tumours larger than 3 cm • high risk tumours – ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000436-15 Sponsor Protocol Number: DD-study-3 Start Date*: 2015-05-18
    Sponsor Name:Aarhus Universitet
    Full Title: Photodynamic diagnosis (PDD) in flexible cystoscopy – a randomized study with focus on significant recurrence
    Medical condition: Patients with non muscle invasive bladder cancer in their first year after the diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-003270-80 Sponsor Protocol Number: H-2-2011-063 Start Date*: 2011-08-25
    Sponsor Name:Kirsten Rasmussen
    Full Title: Effect of colloid versus crystalloid on coagulation in elective urological surgery. A randomised clinical trial.
    Medical condition: Neoplasma malignum vesicae urinariae
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005004 Bladder cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003517-42 Sponsor Protocol Number: SPI-1012 Start Date*: 2011-11-23
    Sponsor Name:Spectrum Pharmaceuticals, Inc
    Full Title: A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patie...
    Medical condition: The medical condition under investigation is noninvasive bladder cancer in patients undergoing transurethral resection of bladder tumor/tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005007 Bladder cancer stage 0, without cancer in situ PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000782-35 Sponsor Protocol Number: 28-02 (ZKS000429) Start Date*: 2009-01-21
    Sponsor Name:Verein fuer Krebsfoschung (Society for Cancer Research)
    Full Title: Dose-escalating study to determine the maximum tolerated dose (MTD) of the mistletoe extract WEME 200 mg for intravesical instillation in patients with completely resected (R0) superficial bladder ...
    Medical condition: Patients after transurethral R0-resection (TUR) of a histologically confirmed superficial bladder carcinoma (pTa low grade [multilocular or recurrence], pT1 low grade); re-resections included.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046518 Urinary bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015404-26 Sponsor Protocol Number: SPI-611 Start Date*: 2009-11-12
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial of Single-Dose Intravesical EOquinâ as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoi...
    Medical condition: The medical condition under investigation is noninvasive bladder cancer in patients undergoing transurethral resection of bladder tumor.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005005 Bladder cancer recurrent LLT
    9.1 10005007 Bladder cancer stage 0, without cancer in situ LLT
    9.1 10005003 Bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-001775-35 Sponsor Protocol Number: MC-BCG.4/HBCA Start Date*: 2007-07-12
    Sponsor Name:medac GmbH
    Full Title: Intravesical instillation of BCG strain RIVM versus TICE for prevention of recurrenec in patients with high-risk papillary superficial carcinomas of the urinary bladder. A randomised phase II clini...
    Medical condition: immunostimulating adjuvant therapy of superficial carcinomas of the urinary bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046518 Urinary bladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:21:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA